Home-grown firm submits its Alzheimer's drug for FDA approval

Yale-NUS College's Assistant Professor Jan Gruber and research fellow Emelyne Teo with a magnified image of the tiny worm called Caenorhabditis elegans. The researchers worked with the worms, which share many similarities with humans at the molecular level, to find a way to fight Alzheimer's disease. ST PHOTO: KELVIN CHNG
Social Affairs Correspondent
Updated
Published
July 1, 2020 at 5:00 AM
New: Gift this subscriber-only story to your friends and family

At least 30 people with Alzheimer's disease in Singapore have tried an experimental drug, developed by a local firm, that is said to slow down progression of the brain disorder.

Currently, drugs on the market treat only the symptoms without affecting the course of the disease.

Already a subscriber? 

Dive deeper at $0.99/month

Want more exclusives, sharp insights into what's happening at home and abroad? Subscribe to stay informed.

ST One Digital Package - Monthly

$9.90 $0.99/month

No contract

$0.99/month for the first 3 months, $9.90/month thereafter. T&Cs apply.

Subscribe now

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • 2-week e-paper archive so you never miss out on any topic that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Straits Times on July 01, 2020, with the headline Home-grown firm submits its Alzheimer's drug for FDA approval. Subscribe

Available for
iPhones and iPads
Available in
Google Play

MCI (P) 031/10/2021, MCI (P) 032/10/2021. Published by SPH Media Limited, Co. Regn. No. 202120748H. Copyright © 2021 SPH Media Limited. All rights reserved.

Back to the top